Blog
RSS FeedPosted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 14 Feb 2019
NICE provides first scientific advice on patient preference study design
14 February 2019 - The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided ...
Posted by Michael Wonder on 14 Feb 2019
Germany agrees on new pharmaceutical bill
13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...
Posted by Michael Wonder on 14 Feb 2019
OIA responses: exploring ways to publish them
14 February 2019 - To support New Zealand's commitment to open government, PHARMAC is exploring ways to publish more of ...
Posted by Michael Wonder on 14 Feb 2019
Universal medicine access through lump-sum remuneration — Australia’s approach to hepatitis C
14 February 2019 - Australia’s agreement to spend about 1 billion Australian dollars (U.S.$766 million) over 5 years in exchange for ...
Posted by Michael Wonder on 13 Feb 2019
PHARMAC to review its practices following criticism of breast cancer drug funding
13 February 2019 - The government's drug-buying agency has announced it has begun an internal review following a petition and ...
Posted by Michael Wonder on 12 Feb 2019
Cystic fibrosis scandal: fury over US firm's 'refusal' to set price for life-saving drugs
11 February 2019 - A US drugs firm is "playing with people's lives" by refusing to do a deal over Orkambi, ...
Posted by Michael Wonder on 12 Feb 2019
Yescarta rejected among other SMC decisions
12 February 2019 - Gilead's CAR-T therapy Yescarta (axicabtagene ciloleucel) has been rejected by the Scottish Medicines Consortium (SMC) for ...
Posted by Michael Wonder on 12 Feb 2019
Breast cancer patients die while waiting for medicines
12 February 2019 - Women with terminal breast cancer will be sharing their heartfelt stories with MPs about the dire ...
Posted by Michael Wonder on 11 Feb 2019
SMC - February 2019 decisions
11 February 2019 - A medicine used to treat a rare blood cancer in children and young adults has today ...
Posted by Michael Wonder on 11 Feb 2019
Government should spend money on cancer treatment, not gender reassignment
11 February 2019 - Should the government fund gender reassignment surgeries? ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...
Posted by Michael Wonder on 10 Feb 2019
Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology
7 February 2019 - Patient involvement in drug evaluation decision making is increasing. ...
Posted by Michael Wonder on 09 Feb 2019
U.S. PhRMA's fight to prevent lower Canadian drug prices
9 February 2019 - Drug industry turns up heat against Canada's drug price reforms. ...